8-K: Quince Therapeutics Reports Fiscal Year 2024 Results and Provides Business Update: NEAT Trial Enrollment Exceeds 50%

Quince Therapeutics announces its fiscal year 2024 financial results, highlighting progress in its Phase 3 NEAT clinical trial and an expected cash runway into 2026.

Summary

• Quince Therapeutics reported its fiscal year 2024 financial results and provided a business update on March 24, 2025.
• The Phase 3 NEAT clinical trial has exceeded 50% enrollment, with 71 participants screened and 61 randomized.
• New study site activations are expected to accelerate screenings and randomization, targeting completion in the second quarter of 2025.
• Topline results from the NEAT study are anticipated in the fourth quarter of 2025.
• The company's cash position was $40.8 million as of December 31, 2024, expected to provide operating runway through Phase 3 topline results into 2026.
• A Phase 2 clinical trial is being designed to evaluate eDSP for Duchenne muscular dystrophy (DMD), with initiation planned for 2025.
• The company reported R&D expenses of $18.6 million and G&A expenses of $17.6 million for the fiscal year ended December 31, 2024.
• The net loss for the year was $56.8 million, or $1.31 per basic and diluted share.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in the NEAT trial and the expected cash runway. However, the net loss and the need for potential future financing temper the overall sentiment.

Positives

• The Phase 3 NEAT clinical trial is progressing well, exceeding 50% enrollment.
• New site activations are expected to accelerate enrollment in the NEAT trial.
• The company has sufficient cash to fund operations through Phase 3 NEAT topline results into 2026.
• A Phase 2 clinical trial for DMD is planned for 2025, potentially expanding the application of eDSP.
• The company strengthened its intellectual property portfolio with a Notice of Allowance from the USPTO, extending patent claims into 2036.
• Fast Track designation from the FDA for eDSP in A-T was granted in June 2024.
• Long-term safety data from patients with A-T treated with eDSP for a minimum of 24 months was published in Frontiers in Neurology in January 2025.

Negatives

• The company reported a net loss of $56.8 million for the fiscal year ended December 31, 2024.
• The company used $31.9 million in operating activities for the year ended December 31, 2024.

Risks

• The success of the Phase 3 NEAT clinical trial is crucial for regulatory submissions and future growth.
• The company's ability to secure additional funding and financial support is important for extending its cash runway.
• Clinical trials are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects.

Future Outlook

Quince expects its existing cash runway to be sufficient to fund the company's capital efficient development plan through Phase 3 NEAT topline results and into 2026, and plans to be opportunistic from a financing perspective to extend its existing cash runway.

Management Comments

• Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, 'Our Phase 3 pivotal NEAT clinical trial has exceeded 50% enrollment with 71 participants screened and 61 randomized.'
• Recent and upcoming new site activations are expected to accelerate enrollment through our target completion date in the second quarter of 2025.
• Assuming target enrollment completion, topline results from the NEAT study are anticipated in the fourth quarter of 2025.

Industry Context

Quince Therapeutics is focused on rare diseases, specifically Ataxia-Telangiectasia (A-T) and Duchenne muscular dystrophy (DMD), which have high unmet medical needs. The company's eDSP program targets these conditions, and the progress of the NEAT trial is a key milestone. The company is also exploring capital efficient study approaches and opportunistic funding opportunities.

Comparison to Industry Standards

• It is difficult to compare Quince Therapeutics directly to industry standards without knowing the specific details of their clinical trial design and endpoints.
• However, the company's focus on rare diseases aligns with a growing trend in the biotechnology industry, where companies are targeting niche markets with high unmet needs.
• Companies like Sarepta Therapeutics and BioMarin Pharmaceutical are also focused on rare diseases and have achieved commercial success.
• Quince's approach of using a patient's own biology for treatment is also a growing trend in the industry, with companies like bluebird bio and CRISPR Therapeutics developing gene therapies and cell therapies.

Stakeholder Impact

• Positive results from the NEAT trial could significantly benefit patients with Ataxia-Telangiectasia (A-T).
• Shareholders may be impacted by the company's financial performance and any potential future financing activities.
• Employees are impacted by the company's progress and financial stability.

Next Steps

• Accelerate screening and randomization in the NEAT trial with new site activations.
• Report Phase 3 NEAT topline results in the fourth quarter of 2025.
• Initiate a DMD Phase 2 study in 2025.
• Submit an NDA to the FDA and an MAA to the EMA in 2026, assuming positive study results.

Key Dates

Keywords

Quince Therapeutics, NEAT clinical trial, Ataxia-Telangiectasia, eDSP, Financial Results, Duchenne muscular dystrophy, Rare diseases, Biotechnology